Navigation Links
NeurogesX to Pursue Expanded U.S. Label for Qutenza® (capsaicin) 8% Patch in HIV-Associated Neuropathy
Date:10/18/2010

i>.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to statements about NeurogesX' plans to submit a supplemental NDA to the FDA and the timing of such submission; expected data to be included in such submission; additional market reach of expanding the Qutenza label to include treatment of pain associated with HIV-AN and the ability to use the U.S. sales force and other relationships to facilitate commercialization of Qutenza in the potential new indication. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: difficulties or delays in the submission of the supplemental NDA for Qutenza; data submitted may not be sufficient to support FDA approval of Qutenza in the treatment of pain associated with HIV-AN; market acceptance of Qutenza in already approved indications may not be sufficient to support further pursuit of an expanded label for Qutenza, including as a result of physician or patient reluctance to use Qutenza; Qutenza and NeurogesX' other product candidates may have unexpected adverse side effects; and potential alternative therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX, Inc.

Stephen Ghiglieri

Executive Vice President, COO

and CFO

(650) 358-3310




The Ruth Group

Sara Pellegrino (investor
'/>"/>


SOURCE NeurogesX
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeurogesX to Present at J.P. Morgan Health Care Conference
2. NeurogesX to Present at Piper Jaffray Health Care Conference
3. NeurogesX Reports Third Quarter 2009 Results
4. NeurogesX to Present at Two November Conferences
5. NeurogesX to Present at UBS Global Life Sciences Conference
6. NeurogesX to Present at Upcoming Fall Conferences
7. NeurogesX Appoints New Board Director and Audit Committee Chairman
8. NeurogesX Reports Second Quarter 2009 Results
9. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
10. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
11. NeurogesX Added to Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. ... together with two institutes from the National Institutes of ... for bringing safer, more effective treatments to patients on ... Center for Advancing Translational Sciences (NCATS) and the National ...
(Date:1/14/2014)... 2014 In recent years, growing suspicion ... in product development and promotion has led to unprecedented ... fueled by concerns about the insidious impact of commercialization ... spectacular fines to the world’s biggest pharmas for illegal ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Global ... developing innovative information technology solutions for patients, physicians, ... care stakeholders, announced today the signing of a ... Food and Drug Administration (FDA). This initiative ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... PITTSBURGH , Jan. 28 Today Carnegie Science ... sponsored by Eaton Corporation. , Carnegie Science Center established ... promote outstanding science and technology achievements in western Pennsylvania ... Awards have honored the accomplishments of more than 250 individuals ...
... , , TORONTO , Jan. ... biopharmaceutical company developing innovative immune-based biologics, today announced that ... of Directors as an independent director. Trillium Chairman Dr. ... pleasure to welcome such an experienced biotech executive as ...
... , , BEIJING , Jan. ... "Company"), a leading China -based vaccine manufacturer,announced today that it ... per common share. Sinovac has granted the underwriters a,30-day ... the same terms and conditions. This reflects an increase in ...
Cached Biology Technology:2010 Carnegie Science Awardees Announced 22010 Carnegie Science Awardees Announced 32010 Carnegie Science Awardees Announced 42010 Carnegie Science Awardees Announced 52010 Carnegie Science Awardees Announced 6Trillium adds industry veteran Dr. Mike Gresser to its Board of Directors 2Trillium adds industry veteran Dr. Mike Gresser to its Board of Directors 3Sinovac Announces Upsizing and Pricing of Common Share Offering 2Sinovac Announces Upsizing and Pricing of Common Share Offering 3
(Date:4/22/2014)... A team of nanotechnology researchers at the University of ... nanostructures and arrays using RNA. , The research, ... Endowed Chair in Nanobiotechnology at the UK College of ... article titled "RNA as a Boiling-Resistant Anionic Polymer Material ... coauthored by Emil F. Khisamutdinov and Daniel L. Jasinski. ...
(Date:4/22/2014)... As President Barack Obama begins a trip to ... strategic pivot to the Pacific, officials at the ... Asia-Pacific Technology and Education Partnership (APTEP) as an ... United States and its allies in the region. ... partnerships across the Asia-Pacific region, supports the development ...
(Date:4/22/2014)... another way of asking him or her to behave ... cells of the immune system tend to misbehave with ... these cells are known to misbehave similarly during spaceflight, ... cells to better understand how our immune systems change ... on Aging, part of the National Institutes of Health, ...
Breaking Biology News(10 mins):RNA shows potential as boiling-resistant anionic polymer material for nanoarchitectures 2Full power: Alternative energy partnerships flourish in Asia 2Full power: Alternative energy partnerships flourish in Asia 3For an immune cell, microgravity mimics aging 2For an immune cell, microgravity mimics aging 3For an immune cell, microgravity mimics aging 4For an immune cell, microgravity mimics aging 5
... New Haven, Conn.Yale University engineers have found that the ... cluster in the blood and stimulate the body,s natural ... article of the April 20 issue of the journal ... treatment used to boost the body,s ability to fight ...
... factors in tinnitus is low, according to new research from ... large population-based study to measure the heritability of tinnitus. ... what degree it is hereditary. Prevalence of tinnitus was 15.1 ... Tinnitus is a symptom with a variety of underlying ...
... fly around the world every day capturing images of ... days these satellites have provided visible and infrared imagery ... Iceland. Eyjafjallajkull is pronounced similar to "EYE-a-fyat-la-yu-goot," and ... eruptions are important sources of gases, such as sulphur ...
Cached Biology News:Carbon nanotubes boost cancer-fighting cells 22 NASA Satellites Capture Last 3 Days of Eyjafjallajokull's Ash Plume 2
... White lyophilized solid. PROTECT FROM LIGHT. ... inhibitor of γ-secretase. Equipotently inhibits the release ... = 2.6 μM) and Aβ x-42 ... HEK293 cells stably transfected with the Amyloid ...
...
Corticoliberin...
Microlite 2+ Plate, round bottom; an irradiated, high binding surface with enhanced dynamic range, extra high reflectivity and minimal cross talk for low signal luminescent reactions....
Biology Products: